Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with recurrent endometrial cancer (a type of uterine cancer that has come back), confirmed by laboratory testing of tissue, including specific subtypes such as serous, endometrioid, carcinosarcoma, or clear cell.
• People whose cancer has been tested and found to have a normal DNA repair system (called "mismatch repair proficient"), confirmed through laboratory testing.
• People whose cancer has already been treated with a first round of chemotherapy (platinum-based) combined with immunotherapy, and that treatment has stopped working.
• People who have had advanced genetic testing (called next-generation sequencing) done on their tumour, either from the original diagnosis or when the cancer came back.
• People with a general health and activity level rated between 0 and 3 on a standard medical scale (ranging from fully active to capable of limited self-care — confirm with trial site for details).
• People aged 18 years or older.
• Women who are not able to become pregnant, or women who could become pregnant but agree to use contraception as required by the trial; participants must not be pregnant or breastfeeding at the time of joining.
• People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines.
• People whose blood and organ function results meet minimum levels, including: sufficient red blood cells, white blood cells, and platelets; adequate kidney function; and liver chemical levels within an acceptable range (confirm with trial site for exact values).
• People who are willing and able to provide written consent to participate.
• People who have waited at least 3 weeks since finishing any previous cancer treatment before joining the trial.

Who may not be able to join:

• People diagnosed with uterine sarcoma (a different type of uterine cancer).
• People who have active cancer spread to the brain or the lining around the brain or spinal cord.
• People who have had a serious allergic reaction in the past to pembrolizumab, lenvatinib, or any ingredients in those medicines.
• People who have an active autoimmune disease (where the immune system attacks the body) that has required long-term steroid treatment for more than 3 months in the past 6 months.
• People who are pregnant or breastfeeding at the time of joining the trial.
• People who have previously been treated with lenvatinib or similar medicines that target a pathway called VEGFR.
• People who are currently taking part in another clinical trial or receiving other cancer treatments, with the exception of hormonal therapy for breast cancer.
• People who have another serious uncontrolled health condition, such as an active infection, that could affect safe participation in the trial.
• People whose blood pressure has averaged above certain levels across their last three recorded measurements (confirm with trial site for exact thresholds).
• People who have had a serious heart event within the past 12 months, such as a heart attack, unstable chest pain, or significant heart failure.
• People who have had an organ transplant or who take immune-suppressing medicines in a way that could interfere with the trial treatments.
• People who have had another type of cancer in the past 2 years, except for certain common skin cancers (non-melanoma skin cancer).

Important: Always verify eligibility with the trial site directly before applying.